{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:44:17Z","timestamp":1793371457062,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. \u2018Classic\u2019 serotonergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus of action at the 5-HT2A receptor, form the main focus of this movement, but substances including ketamine, 3,4-Methylenedioxymethamphetamine (MDMA) and ibogaine also hold promise. The modern phase of development of these treatment modalities in the early 21st century has occurred concurrently with the wider use of advanced human neuroscientific research methods; principally neuroimaging. This can potentially enable assessment of drug and therapy brain effects with greater precision and quantification than any previous novel development in psychiatric pharmacology. We outline the major trends in existing data and suggest the modern development of PT has benefitted greatly from the use of neuroimaging. Important gaps in existing knowledge are identified, namely: the relationship between acute drug effects and longer-term (clinically-relevant) effects, the precise characterisation of effects at the 5-HT2A receptor and relationships with functional\/clinical effects, and the possible impact of these compounds on neuroplasticity. A road-map for future research is laid out, outlining clinical studies which will directly address these three questions, principally using combined Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) methods, plus other adjunct techniques. Multimodal (PET\/MRI) studies using modern PET techniques such as the 5-HT2A-selective ligand [11\u2009C]Cimbi-36 (and other ligands sensitive to neuroplasticity changes) alongside MRI measures of brain function would provide a \u2018molecular-functional-clinical bridge\u2019 in understanding. Such results would help to resolve some of these questions and provide a firmer foundation for the ongoing development of PT.<\/jats:p>","DOI":"10.1038\/s41380-023-02271-0","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T04:02:54Z","timestamp":1695787374000},"page":"3573-3580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Neuroimaging in psychedelic drug development: past, present, and future"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-6274","authenticated-orcid":false,"given":"Matthew B.","family":"Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-6687","authenticated-orcid":false,"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6211","authenticated-orcid":false,"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"2271_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43450-020-00107-4","volume":"31","author":"K Hardy","year":"2021","unstructured":"Hardy K. Paleomedicine and the Evolutionary Context of Medicinal Plant Use. Rev Brasileira de Farmacogn. 2021;31:1\u201315.","journal-title":"Rev Brasileira de Farmacogn"},{"key":"2271_CR2","doi-asserted-by":"crossref","unstructured":"Sessa B. The History of Psychedelics in Medicine. In: von Heyden M, Jungaberle H, Maji\u0107 T, editors. Handbuch Psychoaktive Substanzen. Berlin, Heidelberg: Springer; 2016. p. 1\u201326.","DOI":"10.1007\/978-3-642-55214-4_96-1"},{"key":"2271_CR3","first-page":"495","volume":"3","author":"TA Ban","year":"2007","unstructured":"Ban TA. Fifty years chlorpromazine: A historical perspective. Neuropsychiatr Dis Treat. 2007;3:495\u2013500.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2271_CR4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/0019-5545.82567","volume":"53","author":"CT Ramachandraih","year":"2011","unstructured":"Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: From MAOIs to SSRIs and more. Indian J Psychiatry. 2011;53:180\u2013182.","journal-title":"Indian J Psychiatry"},{"key":"2271_CR5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1310-3990","volume":"54","author":"DE Nichols","year":"2021","unstructured":"Nichols DE, Walter H. The History of Psychedelics in Psychiatry. Pharmacopsychiatry. 2021;54:151\u201366.","journal-title":"Pharmacopsychiatry"},{"key":"2271_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370505000703","volume":"50","author":"E Dyck","year":"2005","unstructured":"Dyck E. Flashback: Psychiatric experimentation with LSD in historical perspective. Can J Psychiatry. 2005;50:381\u20138.","journal-title":"Can J Psychiatry"},{"key":"2271_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3934\/publichealth.2015.1.142","volume":"1","author":"A Golub","year":"2015","unstructured":"Golub A, Bennett AS, Elliott L, Golub A, Bennett AS, Elliott L. Beyond Americas war on drugs: developing public policy to navigate the prevailing pharmacological revolution. AIMS Public Health. 2015;1:142.","journal-title":"AIMS Public Health"},{"key":"2271_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jhmas\/jrs050","volume":"69","author":"M Oram","year":"2014","unstructured":"Oram M. Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962. J Hist Med Allied Sci. 2014;69:221\u201350.","journal-title":"J Hist Med Allied Sci"},{"key":"2271_CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","volume":"14","author":"DJ Nutt","year":"2013","unstructured":"Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013;14:577\u201385.","journal-title":"Nat Rev Neurosci"},{"key":"2271_CR10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.pa.09.040169.001325","volume":"9","author":"M Fink","year":"1969","unstructured":"Fink M. EEG and Human Psychopharmacology. Annu Rev Pharmacol. 1969;9:241\u201358.","journal-title":"Annu Rev Pharmacol"},{"key":"2271_CR11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505\u201311.","journal-title":"Life Sci"},{"key":"2271_CR12","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 1998;9:3897\u2013902.","journal-title":"NeuroReport"},{"key":"2271_CR13","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","volume":"23","author":"J Gonz\u00e1lez-Maeso","year":"2003","unstructured":"Gonz\u00e1lez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex. J Neurosci. 2003;23:8836\u201343.","journal-title":"J Neurosci"},{"key":"2271_CR14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"Rucker JJH","year":"2018","unstructured":"Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200\u201318.","journal-title":"Neuropharmacology"},{"key":"2271_CR15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2010","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J Psychopharmacol. 2010;25:439\u201352.","journal-title":"J Psychopharmacol"},{"key":"2271_CR16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 2012;109:2138\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2271_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, et al. Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"2271_CR18","first-page":"201518377","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci. 2016;113:201518377.","journal-title":"Proc Natl Acad Sci"},{"key":"2271_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, St\u00e4mpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife. 2018;7:1\u201331.","journal-title":"eLife"},{"key":"2271_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","volume":"78","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Kevin M, Robert L, David E, Wall MB, Bart F, et al. The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labelling and Blood Oxygen Level-Dependent Resting-State Functional Connectivity. Biol Psychiatry. 2015;78:554\u201362.","journal-title":"Biol Psychiatry"},{"key":"2271_CR21","doi-asserted-by":"crossref","first-page":"20140873","DOI":"10.1098\/rsif.2014.0873","volume":"11","author":"G Petri","year":"2014","unstructured":"Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, et al. Homological scaffolds of brain functional networks. J R Soc Interface. 2014;11:20140873.","journal-title":"J R Soc Interface"},{"key":"2271_CR22","doi-asserted-by":"crossref","first-page":"117653","DOI":"10.1016\/j.neuroimage.2020.117653","volume":"227","author":"AI Luppi","year":"2021","unstructured":"Luppi AI, Carhart-Harris RL, Roseman L, Pappas I, Menon DK, Stamatakis EA. LSD alters dynamic integration and segregation in the human brain. NeuroImage. 2021;227:117653.","journal-title":"NeuroImage"},{"key":"2271_CR23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316\u201344.","journal-title":"Pharmacol Rev"},{"key":"2271_CR24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","volume":"29","author":"MA Geyer","year":"2008","unstructured":"Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008;29:445\u201353.","journal-title":"Trends Pharmacol Sci"},{"key":"2271_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/brain\/awab406","volume":"145","author":"MK Doss","year":"2022","unstructured":"Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2022;145:441\u201356.","journal-title":"Brain"},{"key":"2271_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","volume":"56","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56:495\u2013507.","journal-title":"Brain Res Bull"},{"key":"2271_CR27","doi-asserted-by":"publisher","unstructured":"Kaelen M, Lorenz R, Barrett F, Roseman L, Orban C, Santos-Ribeiro A, et al. Effects of LSD on music-evoked brain activity. bioRxiv. 2017. https:\/\/doi.org\/10.1101\/153031.","DOI":"10.1101\/153031"},{"key":"2271_CR28","doi-asserted-by":"publisher","unstructured":"Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, et al. LSD modulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology. 2016. https:\/\/doi.org\/10.1016\/j.euroneuro.2016.03.018.","DOI":"10.1016\/j.euroneuro.2016.03.018"},{"key":"2271_CR29","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","volume":"113","author":"KH Preller","year":"2016","unstructured":"Preller KH, Pokorny T, Hock A, Kraehenmann R, St\u00e3mpfli P, Seifritz E, et al. Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci USA. 2016;113:5119\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2271_CR30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1017\/S1461145713001405","volume":"17","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17:527\u201340.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2271_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules26092451","volume":"26","author":"P Cumming","year":"2021","unstructured":"Cumming P, Scheidegger M, Dornbierer D, Palner M, Quednow BB, Martin-Soelch C. Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules. 2021;26:1\u201326.","journal-title":"Molecules"},{"key":"2271_CR32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11307-012-0609-4","volume":"15","author":"A Ettrup","year":"2013","unstructured":"Ettrup A, Holm S, Hansen M, Wasim M, Santini MA, Palner M, et al. Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36. Mol Imaging Biol. 2013;15:4.","journal-title":"Mol Imaging Biol"},{"key":"2271_CR33","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","volume":"34","author":"A Ettrup","year":"2014","unstructured":"Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J Cereb Blood Flow Metab. 2014;34:1188\u201396.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2271_CR34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neuroimage.2013.08.035","volume":"84","author":"SJ Finnema","year":"2014","unstructured":"Finnema SJ, Stepanov V, Ettrup A, Nakao R, Amini N, Svedberg M, et al. Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. NeuroImage. 2014;84:342\u201353.","journal-title":"NeuroImage"},{"key":"2271_CR35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41386-019-0567-5","volume":"45","author":"D Erritzoe","year":"2020","unstructured":"Erritzoe D, Ashok AH, Searle GE, Colasanti A, Turton S, Lewis Y, et al. Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology. 2020;45:804\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"2271_CR36","doi-asserted-by":"publisher","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2 A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019. https:\/\/doi.org\/10.1038\/s41386-019-0324-9.","DOI":"10.1038\/s41386-019-0324-9"},{"key":"2271_CR37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man\u2014A PET Study with [11C]raclopride. Neuropsychopharmacology. 1999;20:424\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"2271_CR38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(98)00089-X","volume":"20","author":"E Gouzoulis-Mayfrank","year":"1999","unstructured":"Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and D-methamphetamine in healthy volunteers: A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999;20:565\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"2271_CR39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"MK Madsen","year":"2020","unstructured":"Madsen MK, Fisher PMD, Stenb\u00e6k DS, Kristiansen S, Burmester D, Lehel S, et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol. 2020;33:71\u201380.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2271_CR40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881120959609","volume":"35","author":"DS Stenb\u00e6k","year":"2021","unstructured":"Stenb\u00e6k DS, Madsen MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, et al. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol. 2021;35:459\u201368.","journal-title":"J Psychopharmacol"},{"key":"2271_CR41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archgenpsychiatry.2011.56","volume":"68","author":"D Erritzoe","year":"2011","unstructured":"Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, et al. In vivo imaging of cerebral serotonin transporter and serotonin 2A receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or \u2018Ecstasy\u2019) and hallucinogen users. Arch Gen Psychiatry. 2011;68:562\u201376.","journal-title":"Arch Gen Psychiatry"},{"key":"2271_CR42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"2271_CR43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78:481\u20139.","journal-title":"JAMA Psychiatry"},{"key":"2271_CR44","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N. Engl J Med. 2021;384:1402\u201311.","journal-title":"N. Engl J Med"},{"key":"2271_CR45","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187.","journal-title":"Sci Rep"},{"key":"2271_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","volume":"142","author":"L Roseman","year":"2018","unstructured":"Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263\u20139.","journal-title":"Neuropharmacology"},{"key":"2271_CR47","doi-asserted-by":"crossref","unstructured":"Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34:1\u201314.","DOI":"10.1177\/0269881119895520"},{"key":"2271_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jad.2023.04.081","volume":"333","author":"MB Wall","year":"2023","unstructured":"Wall MB, Lam C, Ertl N, Kaelen M, Roseman L, Nutt DJ, et al. Increased low-frequency brain responses to music after psilocybin therapy for depression. J Affect Disord. 2023;333:321\u201330.","journal-title":"J Affect Disord"},{"key":"2271_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10:1\u201314.","journal-title":"Sci Rep"},{"key":"2271_CR50","doi-asserted-by":"publisher","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. 2022. https:\/\/doi.org\/10.1038\/s41591-022-01744-z.","DOI":"10.1038\/s41591-022-01744-z"},{"key":"2271_CR51","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1021\/acschemneuro.2c00461","volume":"13","author":"MK Doss","year":"2022","unstructured":"Doss MK, Barrett FS, Corlett PR. Skepticism about Recent Evidence That Psilocybin \u2018Liberates\u2019 Depressed Minds. ACS Chem Neurosci. 2022;13:2540\u20133.","journal-title":"ACS Chem Neurosci"},{"key":"2271_CR52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/YCO.0000000000000467","volume":"32","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL. How do psychedelics work? Curr Opin Psychiatry. 2019;32:16\u201321.","journal-title":"Curr Opin Psychiatry"},{"key":"2271_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-01158-w","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"2271_CR54","doi-asserted-by":"crossref","first-page":"104689","DOI":"10.1016\/j.neubiorev.2022.104689","volume":"138","author":"DE-W McCulloch","year":"2022","unstructured":"McCulloch DE-W, Knudsen GM, Barrett FS, Doss MK, Carhart-Harris RL, Rosas FE, et al. Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neurosci Biobehav Rev. 2022;138:104689.","journal-title":"Neurosci Biobehav Rev"},{"key":"2271_CR55","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/j.euroneuro.2020.09.589","volume":"40","author":"NR Raval","year":"2020","unstructured":"Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, et al. P.804A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Eur Neuropsychopharmacol. 2020;40:S453\u2013S454.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2271_CR56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","volume":"42","author":"LR Aleksandrova","year":"2021","unstructured":"Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"2271_CR57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5498\/wjp.v11.i6.201","volume":"11","author":"H Artin","year":"2021","unstructured":"Artin H, Zisook S, Ramanathan D. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatry. 2021;11:201\u201314.\u00a0https:\/\/www.wjgnet.com\/2220-3206\/full\/v11\/i6\/201.htm","journal-title":"World J Psychiatry"},{"key":"2271_CR58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. J Psychopharmacol. 2017;31:1091\u2013120.","journal-title":"J Psychopharmacol"},{"key":"2271_CR59","first-page":"1575","volume":"12","author":"CMH de Vos","year":"2021","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021;12:1575.","journal-title":"Front Psychiatry"},{"key":"2271_CR60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"NRPW Hutten","year":"2021","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al. Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacol Transl Sci. 2021;4:461\u20136.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2271_CR61","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fpsyg.2019.01234","volume":"10","author":"RN de Almeida","year":"2019","unstructured":"de Almeida RN, Galv\u00e3o ACdeM, da Silva FS, Silva EAdosS, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front Psychol. 2019;10:1234.","journal-title":"Front Psychol"},{"key":"2271_CR62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","volume":"21","author":"I Byock","year":"2018","unstructured":"Byock I. Taking Psychedelics Seriously. J Palliat Med. 2018;21:417\u201321.\u00a0https:\/\/www.liebertpub.com\/doi\/10.1089\/jpm.2017.0684","journal-title":"J Palliat Med"},{"key":"2271_CR63","doi-asserted-by":"publisher","unstructured":"McClure-Begley TD, Roth BL The promises and perils of psychedelic pharmacology for psychiatry. Nature Reviews Drug Discovery. 2022. https:\/\/doi.org\/10.1038\/s41573-022-00421-7.","DOI":"10.1038\/s41573-022-00421-7"},{"key":"2271_CR64","first-page":"180","volume":"21","author":"S Crunkhorn","year":"2022","unstructured":"Crunkhorn S. Designing nonhallucinogenic psychedelic analogues. Nat Rev Drug Discov. 2022;21:180.","journal-title":"Nat Rev Drug Discov"},{"key":"2271_CR65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","volume":"375","author":"D Cao","year":"2022","unstructured":"Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022;375:403\u201311.","journal-title":"Science"},{"key":"2271_CR66","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fpsyt.2021.735523","volume":"12","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalh\u00e3es FJC, et al. Study Protocol for \u201cPsilocybin as a Treatment for Anorexia Nervosa: A Pilot Study\u201d. Front Psychiatry. 2021;12:1770.","journal-title":"Front Psychiatry"},{"key":"2271_CR67","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/mp300570z","volume":"10","author":"AK Deo","year":"2013","unstructured":"Deo AK, Theil FP, Nicolas JM. Confounding parameters in preclinical assessment of blood-brain barrier permeation: An overview with emphasis on species differences and effect of disease states. Mol Pharmaceutics. 2013;10:1581\u201395.","journal-title":"Mol Pharmaceutics"},{"key":"2271_CR68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.neuroimage.2012.03.075","volume":"62","author":"BG Jenkins","year":"2012","unstructured":"Jenkins BG. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. NeuroImage. 2012;62:1072\u201385.","journal-title":"NeuroImage"},{"key":"2271_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2015.00167","volume":"9","author":"JH Bourke","year":"2015","unstructured":"Bourke JH, Wall MB. phMRI: methodological considerations for mitigating potential confounding factors. Front Neurosci. 2015;9:1\u20137.","journal-title":"Front Neurosci"},{"key":"2271_CR70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd2027","volume":"5","author":"D Borsook","year":"2006","unstructured":"Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov. 2006;5:411\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"2271_CR71","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuroimage.2018.05.011","volume":"176","author":"L Demetriou","year":"2018","unstructured":"Demetriou L, Kowalczyk OS, Tyson G, Bello T, Newbould RD, Wall MB. A comprehensive evaluation of increasing temporal resolution with multiband-accelerated sequences and their effects on statistical outcome measures in fMRI. NeuroImage. 2018;176:404\u201316.","journal-title":"NeuroImage"},{"key":"2271_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2017.00158","volume":"11","author":"N Todd","year":"2017","unstructured":"Todd N, Josephs O, Zeidman P, Flandin G, Moeller S. Functional Sensitivity of 2D Simultaneous Multi-Slice Echo-Planar Imaging: Effects of Acceleration on g-factor and Physiological Noise. Front Neurosci. 2017;11:1\u201314.","journal-title":"Front Neurosci"},{"key":"2271_CR73","doi-asserted-by":"crossref","unstructured":"Esteban O, Markiewicz C, Blair RW, Moodie C, Isik AI, Aliaga AE, et al. FMRIPrep: a robust preprocessing pipeline for functional MRI. bioRxiv. 2018:306951.","DOI":"10.1101\/306951"},{"key":"2271_CR74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2967\/jnumed.119.228080","volume":"61","author":"A Mansur","year":"2020","unstructured":"Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, et al. Characterization of 3 PET tracers for quantification of mitochondrial and synaptic function in healthy human brain: 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J. J Nucl Med. 2020;61:96\u2013103.","journal-title":"J Nucl Med"},{"key":"2271_CR75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2967\/jnumed.113.125328","volume":"55","author":"H Tsukada","year":"2014","unstructured":"Tsukada H, Nishiyama S, Fukumoto D, Kanazawa M, Harada N. Novel PET Probes 18F-BCPP-EF and 18F-BCPP-BF for Mitochondrial Complex I: A PET Study in Comparison with 18F-BMS-747158-02 in Rat Brain. J Nucl Med. 2014;55:473\u201380.","journal-title":"J Nucl Med"},{"key":"2271_CR76","doi-asserted-by":"crossref","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8:348ra96.","journal-title":"Sci Transl Med"},{"key":"2271_CR77","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1152\/ajpcell.00259.2010","volume":"299","author":"A Nowack","year":"2010","unstructured":"Nowack A, Yao J, Custer KL, Bajjalieh SM. SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol - Cell Physiol. 2010;299:960\u20137.","journal-title":"Am J Physiol - Cell Physiol"},{"key":"2271_CR78","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/cercor\/bhy159","volume":"28","author":"A Santuy","year":"2018","unstructured":"Santuy A, Tur\u00e9gano-L\u00f3pez M, Rodr\u00edguez JR, Alonso-Nanclares L, Defelipe J, Merch\u00e1n-P\u00e9rez A. A Quantitative Study on the Distribution of Mitochondria in the Neuropil of the Juvenile Rat Somatosensory Cortex. Cereb Cortex. 2018;28:3673\u201384.","journal-title":"Cereb Cortex"},{"key":"2271_CR79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroimage.2015.08.005","volume":"131","author":"J Hamaide","year":"2016","unstructured":"Hamaide J, De Groof G, Van der Linden A. Neuroplasticity and MRI: A perfect match. NeuroImage. 2016;131:13\u201328.","journal-title":"NeuroImage"},{"key":"2271_CR80","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/mp.2011.29","volume":"16","author":"EA Rabiner","year":"2011","unstructured":"Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011;16:826\u201335.","journal-title":"Mol Psychiatry"},{"key":"2271_CR81","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/nm.3290","volume":"19","author":"HF Wehrl","year":"2013","unstructured":"Wehrl HF, Hossain M, Lankes K, Liu C-C, Bezrukov I, Martirosian P, et al. Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med. 2013;19:1184\u20139.","journal-title":"Nat Med"},{"key":"2271_CR82","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1109\/TRPMS.2018.2852558","volume":"2","author":"A Mansur","year":"2018","unstructured":"Mansur A, Newbould R, Searle GE, Redstone C, Gunn RN, Hallett WA. PET-MR Attenuation Correction in Dynamic Brain PET Using [11C]Cimbi-36: A Direct Comparison with PET-CT. IEEE Trans Radiat Plasma Med Sci. 2018;2:483\u20139.","journal-title":"IEEE Trans Radiat Plasma Med Sci"},{"key":"2271_CR83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol (Oxf, Engl). 2022;36:151\u20138.","journal-title":"J Psychopharmacol (Oxf, Engl)"},{"key":"2271_CR84","first-page":"269","volume":"10","author":"MM Nour","year":"2016","unstructured":"Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. 2016;10:269.","journal-title":"Front Hum Neurosci"},{"key":"2271_CR85","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol. 2019;33:1076\u201387.","journal-title":"J Psychopharmacol"},{"key":"2271_CR86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04764-9","volume":"7","author":"G Loheswaran","year":"2017","unstructured":"Loheswaran G, Barr MS, Zomorrodi R, Rajji TK, Blumberger DM, Foll BL, et al. Impairment of Neuroplasticity in the Dorsolateral Prefrontal Cortex by Alcohol. Sci Rep. 2017;7:1.","journal-title":"Sci Rep"},{"key":"2271_CR87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnhum.2018.00155","volume":"12","author":"B Salavati","year":"2018","unstructured":"Salavati B, Daskalakis ZJ, Zomorrodi R, Blumberger DM, Chen R, Pollock BG, et al. Pharmacological modulation of long-term potentiation-like activity in the dorsolateral prefrontal cortex. Front Hum Neurosci. 2018;12:155.","journal-title":"Front Hum Neurosci"},{"key":"2271_CR88","first-page":"45","volume":"5","author":"RL Sumner","year":"2020","unstructured":"Sumner RL, McMillan R, Spriggs MJ, Campbell D, Malpas G, Maxwell E, et al. Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder. Biol Psychiatry: Cogn Neurosci Neuroimaging. 2020;5:45\u201355.","journal-title":"Biol Psychiatry: Cogn Neurosci Neuroimaging"},{"key":"2271_CR89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/neuro.08.003.2007","volume":"1","author":"AJ Fiocco","year":"2007","unstructured":"Fiocco AJ, Joober R, Poirier J, Lupien S. Polymorphism of the 5-HT2A receptor gene: Association with stress-related indices in healthy middle-aged adults. Front Behav Neurosci. 2007;1:1\u20137.","journal-title":"Front Behav Neurosci"},{"key":"2271_CR90","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fnhum.2015.00575","volume":"9","author":"P Gong","year":"2015","unstructured":"Gong P, Liu J, Blue PR, Li S, Zhou X. Serotonin receptor gene (HTR2A) T102C polymorphism modulates individuals\u2019 perspective taking ability and autistic-like traits. Front Hum Neurosci. 2015;9:575.","journal-title":"Front Hum Neurosci"},{"key":"2271_CR91","doi-asserted-by":"crossref","first-page":"e95856","DOI":"10.1371\/journal.pone.0095856","volume":"9","author":"B Qin","year":"2014","unstructured":"Qin B, Sun Z, Liang Y, Yang Z, Zhong R. The Association of 5-HT2A, 5-HTT, and LEPR Polymorphisms with Obstructive Sleep Apnea Syndrome: A Systematic Review and Meta-Analysis. PLOS ONE. 2014;9:e95856.","journal-title":"PLOS ONE"},{"key":"2271_CR92","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000327602","volume":"64","author":"L Olajossy-Hilkesberger","year":"2011","unstructured":"Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, Olajossy M, Wojcierowski J, Landowski J, et al. Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology. 2011;64:202\u201310.","journal-title":"Neuropsychobiology"},{"key":"2271_CR93","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"2271_CR94","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30:363\u201375.","journal-title":"Int Rev Psychiatry"},{"key":"2271_CR95","doi-asserted-by":"crossref","unstructured":"Martin DA, Nichols CD. The Effects of Hallucinogens on Gene Expression. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behavioral Neurobiology of Psychedelic Drugs, Berlin, Heidelberg: Springer; 2018. p. 137\u201358.","DOI":"10.1007\/7854_2017_479"},{"key":"2271_CR96","doi-asserted-by":"crossref","unstructured":"Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022;239:1945\u201376","DOI":"10.1007\/s00213-022-06083-y"},{"key":"2271_CR97","doi-asserted-by":"publisher","unstructured":"Moujaes F, Preller KH, Ji JL, Murray JD, Berkovitch L, Vollenweider FX, et al. Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans. Biol. Psychiatry. 2022. https:\/\/doi.org\/10.1016\/j.biopsych.2022.10.021.","DOI":"10.1016\/j.biopsych.2022.10.021"},{"key":"2271_CR98","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/nm.4190","volume":"22","author":"A Abi-Dargham","year":"2016","unstructured":"Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. Nat Med. 2016;22:1248\u201355.","journal-title":"Nat Med"},{"key":"2271_CR99","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acsptsci.0c00198","volume":"4","author":"MW Johnson","year":"2021","unstructured":"Johnson MW. Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. ACS Pharmacol Transl Sci. 2021;4:578\u201381.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2271_CR100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17:419\u201324.","journal-title":"Drug Discov Today"},{"key":"2271_CR101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.semnuclmed.2016.09.001","volume":"47","author":"RN Gunn","year":"2017","unstructured":"Gunn RN, Rabiner EA. Imaging in Central Nervous System Drug Discovery. Semin Nucl Med. 2017;47:89\u201398.","journal-title":"Semin Nucl Med"},{"key":"2271_CR102","first-page":"91","volume":"29","author":"D Wong","year":"2008","unstructured":"Wong D, Tauscher J, Gr\u00fcnder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2008;29:91\u201398.","journal-title":"Neuropsychopharmacology"},{"key":"2271_CR103","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/jcbfm.2012.20","volume":"32","author":"T Jones","year":"2012","unstructured":"Jones T, Rabiner EA. The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2012;32:1426\u201354.","journal-title":"J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab"},{"key":"2271_CR104","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-014-0066-y","volume":"4","author":"K Ridler","year":"2014","unstructured":"Ridler K, Cunningham V, Huiban M, Martarello L, Pampols-Maso S, Passchier J, et al. An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography. EJNMMI Res. 2014;4:12.","journal-title":"EJNMMI Res"},{"key":"2271_CR105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/17512433.2020.1772054","volume":"13","author":"KT Greenway","year":"2020","unstructured":"Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol. 2020;13:655\u201370.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2271_CR106","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","volume":"15","author":"R Watts","year":"2020","unstructured":"Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci. 2020;15:92\u2013102.","journal-title":"J Contextual Behav Sci"},{"key":"2271_CR107","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Malievskaia E, Fonzo GA, Nemeroff CB Must Psilocybin Always \u201cAssist Psychotherapy\u201d? AJP. 2023:appi.ajp.20221043.","DOI":"10.1176\/appi.ajp.20221043"},{"key":"2271_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.10.006","volume":"114","author":"A Barsaglini","year":"2014","unstructured":"Barsaglini A, Sartori G, Benetti S, Pettersson-Yeo W, Mechelli A. The effects of psychotherapy on brain function: A systematic and critical review. Prog Neurobiol. 2014;114:1\u201314.","journal-title":"Prog Neurobiol"},{"key":"2271_CR109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.31887\/DCNS.2014.16.1\/mbeauregard","volume":"16","author":"M Beauregard","year":"2014","unstructured":"Beauregard M. Functional neuroimaging studies of the effects of psychotherapy. Dialogues Clin Neurosci. 2014;16:75\u201381.","journal-title":"Dialogues Clin Neurosci"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02271-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:39:06Z","timestamp":1703003946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02271-0","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MBW and ER\u2019s primary employer is Invicro LLC, a contract research organisation that provides research services to the pharmaceutical and biotechnology industries. DE has received consulting fees from Field Trip and Mydecine. DJN has received consulting fees from Algernon and H. Lundbeck and Beckley Psytech, advisory board fees from COMPASS Pathways and lecture fees from Takeda, Otsuka, and Janssen plus owns stock in Alcarelle, Awakn, and Psyched Wellness. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}